Attenuated monocyte IL-10 production in glucose-6-phosphate dehydrogenase-deficient trauma patients

Shock

Volumn 18, Issue 1, 2002, Pages 18-23

  Liese, Amy M ^a   Siddiqi, Muhammad Q ^a   Siegel, John H ^a   Deitch, Edwin A ^a   Spolarics, Zoltán ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Cytokines; G6PD deficiency; Host response; Inflammation; Macrophage; Oxidative stress; Systemic inflammatory response syndrome; Trauma

Indexed keywords

GAMMA INTERFERON; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; GENETICS; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INJURY; MALE; METABOLISM; MONOCYTE; PROSPECTIVE STUDY;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; PROSPECTIVE STUDIES; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 0036633185     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200207000-00004     Document Type: Article

References (31)

1. Pandolfi PP, Sonati F, Rivi R, Mason P, Grosveld F, Luzzatto L: Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J 14:5209-5215, 1995.
2. Spolarics Z: Endotoxemia, pentose cycle, and the oxidant/antioxidant balance in the hepatic sinusoid. J Leukoc Biol 63:534-541, 1998.
3. Beutler E: G6PD: population genetics and clinical manifestations. Blood Rev 10:45-52, 1996.
4. Luzzatto L, Mehta A: Glucose-6-phosphate dehydrogenase deficiency. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill. 1995, pp 3367-3398.
5. Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Ong H, Livingston DH, Denny T, Deitch EA: Increased incidence of sepsis and altered monocyte functions in severely injured type A-glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med 29:728-736, 2001.
6. Mordmuller B, Turrini F, Long H, Kremsner PG, Arese P: Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Eur Cytokine Netw 9:239-245, 1998.
7. Liese AM, Siddiqi M, Siegel JH, Denny T, Spolarics Z: Augmented TNF-alpha and IL-10 production by primed human monocytes following interaction with oxidatively modified autologous erythrocytes. J Leukoc Biol 70:289-296, 2001.
8. Baker SP, O'Neill B, Haddon W Jr, Long WB: The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 14:187-196, 1974.
9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
10. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT: Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood 74:2550-2555, 1989.
11. Goldberg B, Stern A, Peisach J: The mechanism of superoxide anion generation by the interaction of phenylhydrazine with hemoglobin. J Biol Chem 251:3045-3051, 1976.
12. Jain SK, Hochstein P. Generation of superoxide radicals by hydrazine: its role in phenylhydrazine-induced hemolytic anemia. Biochim Biophys Acta 586: 128-136, 1979.
13. Horn S, Bashan N, Gopas J: Phagocytosis of phenylhydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-hound immunoglobulins. Blood 78:1818-1825, 1991.
14. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 317:659-665, 1987.
15. Rixen D, Siegel JH, Friedman HP: "Sepsis/SIRS," physiologic classification, severity stratification, relation to cytokine elaboration and outcome prediction in posttrauma critical illness. J Trauma 41:581-598, 1996.
16. Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC, Aminoff D, Montreuil J: Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages: a review. Biochimie 80:173-195, 1998.
17. Luzzatto L: Glucose-6-phosphate dehydrogenase deficiency and the pentose phosphate pathway. In Handin RI, Lux SE, Stossel TP (eds): Blood: Principals and Practice of Hematology. Philadelphia: J.B. Lippincott Company. 1995, pp 1897-1923.
18. Birkenmaier C, Hong YS, Horn JK: Modulation of the endotoxin receptor (CD14) in septic patients. J Trauma 32:473-478, 1992.
19. Randow F, Docke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD: In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 158:2911-2918, 1997.
20. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681, 1997.
21. Volk HD, Reinke P, Docke WD: Clinical aspects: from systemic inflammation to "immunoparalysis." Chem Immunol 74:162-177, 2000.
22. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822, 1991.
23. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153:811-816, 1994.
24. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-IO produced by monocytes. J Exp Med 174:1209-1220, 1991.
25. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208, 1993.
26. Kurtis JD, Lanar DE, Opollo M, Duffy PE: Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun 67:3424-3429, 1999
27. Kobayashi F, Ishida H, Matsui T, Tsuji M: Effects of in vivo administration of anti-IL-10 or anti-IFN-gamma monoclonal antibody on the host defense mechanism against Plasmodium yoelii yoelii infection. J Vet Med Sci 62:583-587, 2000.
28. Helminen M, Lahdenpohja N, Hurme M: Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 180:496-499, 1999.
29. Howell WM, Turner SJ, Bateman AC, Theaker JM: IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25-31, 2001.
30. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1-8, 1997.
31. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP: Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915-3922, 2001.